Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Slugger who wrote (7144)	9/3/1998 4:44:00 AM
From: opalapril	Respond to of 17367

Slugger's analysis has an appealing logic to it, except for the inconvenient but happy fact that aside from drug experiments the quality of diagnostic, surgical, and bedside care for all patients is improving, too (so long as the %%$$#^ health insurance companies "permit" quality treatment.) For this reason my hunch is the final mortality and morbidity rates in both the experimental and placebo groups will show improvement over historic averages. Still, I find it impossible to shake the suspicion that enough anecdotal stories and other indicators over time have become available to some connected with Xoma that by now the company must think it has a fair idea of what's happening. Is there any other basis for this bold supposition? Yes. Human nature.